CLINICAL_TRIALS
trial_result
· 2013-09-10
Clinical Trial Update: BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer [Phase 3]
Summary
The BEATRICE Phase 3 trial evaluating bevacizumab as adjuvant therapy in triple-negative breast cancer has completed, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-09-10